LAB Standard BioTools Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LAB

Price (delayed)

$2.51

Market cap

$199.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.96

Enterprise value

$219.35M

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions ...

Highlights
Standard BioTools's EPS has soared by 58% YoY and by 9% from the previous quarter
The company's net income has surged by 58% YoY and by 10% QoQ
Standard BioTools's equity has shrunk by 110% YoY and by 16% QoQ
LAB's quick ratio is down by 36% YoY and by 16% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.fluidigm.com
Peers: RVTY QTRX PRPO

Key stats

What are the main financial stats of LAB
Market
Shares outstanding
79.4M
Market cap
$199.28M
Enterprise value
$219.35M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.09
Earnings
Revenue
$105.17M
EBIT
-$70.38M
EBITDA
-$66.69M
Free cash flow
-$51.92M
Per share
EPS
-$0.96
Free cash flow per share
-$0.66
Book value per share
-$1.67
Revenue per share
$1.33
TBVPS
$2.89
Balance sheet
Total assets
$339.29M
Total liabilities
$159.75M
Debt
$99.72M
Equity
-$131.72M
Working capital
$118.94M
Liquidity
Debt to equity
-0.76
Current ratio
3.3
Quick ratio
2.81
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-63.4%
Gross margin
45.7%
Net margin
-72%
Operating margin
-72.6%
Efficiency
Return on assets
-20.8%
Return on equity
N/A
Return on invested capital
-35.1%
Return on capital employed
-24.5%
Return on sales
-66.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LAB stock price

How has the Standard BioTools stock price performed over time
Intraday
2.45%
1 week
5.91%
1 month
37.91%
1 year
84.56%
YTD
114.53%
QTD
-13.45%

Financial performance

How have Standard BioTools's revenue and profit performed over time
Revenue
$105.17M
Gross profit
$48.05M
Operating income
-$76.33M
Net income
-$75.73M
Gross margin
45.7%
Net margin
-72%
The company's net income has surged by 58% YoY and by 10% QoQ
The net margin has surged by 56% year-on-year and by 10% since the previous quarter
LAB's operating income is up by 28% YoY and by 9% from the previous quarter
LAB's operating margin is up by 25% year-on-year and by 9% since the previous quarter

Growth

What is Standard BioTools's growth rate over time

Valuation

What is Standard BioTools stock price valuation
P/E
N/A
P/B
N/A
P/S
1.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.09
Standard BioTools's EPS has soared by 58% YoY and by 9% from the previous quarter
Standard BioTools's equity has shrunk by 110% YoY and by 16% QoQ
The P/S is 32% below the 5-year quarterly average of 2.7 but 23% above the last 4 quarters average of 1.5
Standard BioTools's revenue has decreased by 3.7% YoY

Efficiency

How efficient is Standard BioTools business performance
Standard BioTools's ROS has soared by 59% YoY and by 12% from the previous quarter
The company's return on assets has surged by 59% YoY and by 5% QoQ
The return on invested capital has surged by 52% year-on-year

Dividends

What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LAB.

Financial health

How did Standard BioTools financials performed over time
LAB's total assets is 112% greater than its total liabilities
LAB's quick ratio is down by 36% YoY and by 16% from the previous quarter
The current ratio is down by 33% YoY and by 16% from the previous quarter
The debt is 176% greater than the equity
Standard BioTools's equity has shrunk by 110% YoY and by 16% QoQ
LAB's debt to equity has soared by 54% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.